Market capitalization | $886.43m |
Enterprise Value | $895.09m |
P/E (TTM) P/E ratio | 322.37 |
EV/FCF (TTM) EV/FCF | 55.84 |
EV/Sales (TTM) EV/Sales | 4.75 |
P/S ratio (TTM) P/S ratio | 4.71 |
P/B ratio (TTM) P/B ratio | 13.63 |
Revenue growth (TTM) Revenue growth | 15.30% |
Revenue (TTM) Revenue | $188.35m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
10 Analysts have issued a Enfusion forecast:
10 Analysts have issued a Enfusion forecast:
Jun '24 |
+/-
%
|
||
Revenue | 188 188 |
15%
15%
|
|
Gross Profit | 126 126 |
14%
14%
|
|
EBITDA | 19 19 |
17%
17%
|
EBIT (Operating Income) EBIT | 6.41 6.41 |
44%
44%
|
Net Profit | 3.75 3.75 |
33%
33%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Enfusion, Inc. engages in the development of cloud-native multi-tenant software for alternative and institutional investment managers. It is a software-as-a-service firm that develops platform to eliminate technology and information barriers, and simplify investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset. The company was founded in 2006 and is headquartered in Chicago, IL.
Head office | United States |
CEO | Oleg Movchan |
Employees | 1,102 |
Founded | 2006 |
Website | enfusion.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.